Browse history interactively

Page 1

Page 1Revision 1

Page 2

Page 2Revision 2

← Previous editContent deleted Content addedVisualWikitext

Revision as of 20:29, 16 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated '') per Chem/Drugbox validation (report errors or bugs)← Previous edit		Latest revision as of 04:12, 4 June 2024 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers48,667 edits update infobox, links
(102 intermediate revisions by 55 users not shown)
Line 1:		Line 1:
			{{Short description|Medication for the treatment of conditions where certain blood cells are dysfunctional,}}
	{{Drugbox		{{Drugbox
			| Verifiedfields = changed
⚫	| verifiedrevid = 447722270
			| Watchedfields = changed
⚫	| IUPAC_name = 4-amino-1-(2-deoxy-b-<small>D</small>-erythro-pentofuranosyl)-<br>1,3,5-triazin-2(1''H'')-one
		⚫	| verifiedrevid = 450864482
	| image = Decitabine.svg		| image = Decitabine.svg
			| width =
			| alt =
			| caption =
	<!--Clinical data-->		<!--Clinical data-->
	| tradename =		| tradename = Dacogen, Demylocan
	| Drugs.com = {{drugs.com|monograph|decitabine}}		| Drugs.com = {{drugs.com|monograph|decitabine}}
	| MedlinePlus = a608009		| MedlinePlus = a608009
			| DailyMedID = Decitabine
⚫	| pregnancy_category = D
			| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫	| legal_status =
			| pregnancy_AU_comment =
		⚫	| pregnancy_category=
	| routes_of_administration = ]		| routes_of_administration = ]
		⚫	| ATC_prefix = L01
		⚫	| ATC_suffix = BC08
		⚫	| ATC_supplemental =
			| legal_CA = Rx-only
			| legal_CA_comment = <ref>{{cite web | title=Summary Basis of Decision (SBD) for Dacogen | website=] | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00452&lang=en | access-date=29 May 2022}}</ref><ref>{{cite web | title=Summary Basis of Decision (SBD) for Demylocan | website=] | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00436&lang=en | access-date=29 May 2022}}</ref>
			| legal_US = Rx-only
			| legal_US_comment =
			| legal_EU = Rx-only
			| legal_EU_comment = <ref>{{cite web | title=Dacogen EPAR | website=] (EMA) | date=8 June 2006 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen | access-date=4 June 2024}}</ref>
		⚫	| legal_status = Rx-only
	<!--Pharmacokinetic data-->		<!--Pharmacokinetic data-->
Line 19:		Line 37:
	<!--Identifiers-->		<!--Identifiers-->
			| IUPHAR_ligand = 6805
	| CASNo_Ref = {{cascite|correct|CAS}}		| CAS_number_Ref = {{cascite|correct|??}}
	| CAS_number = 2353-33-5		| CAS_number = 2353-33-5
⚫	| ATC_prefix = L01
⚫	| ATC_suffix = BC08
⚫	| ATC_supplemental =
	| PubChem = 451668		| PubChem = 451668
	| DrugBank_Ref = {{drugbankcite|correct|drugbank}}		| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
Line 35:		Line 51:
	| ChEBI_Ref = {{ebicite|correct|EBI}}		| ChEBI_Ref = {{ebicite|correct|EBI}}
	| ChEBI = 50131		| ChEBI = 50131
	| ChEMBL_Ref = {{ebicite|correct|EBI}}		| ChEMBL_Ref = {{ebicite|changed|EBI}}
	| ChEMBL = 66115		| ChEMBL = 1201129
			| synonyms = 5-aza-2'-deoxycytidine
	<!--Chemical data-->		<!--Chemical data-->
		⚫	| IUPAC_name = 4-Amino-1-(2-deoxy-β-<small>D</small>-erythro-pentofuranosyl)-1,3,5-triazin-2(1''H'')-one
	| C=8 | H=12 | N=4 | O=4		| C=8 | H=12 | N=4 | O=4
	| molecular_weight = 228.0859 g/mol
	| smiles = O=C1/N=C(\N=C/N12O((O)C2)CO)N		| smiles = O=C1/N=C(\N=C/N12O((O)C2)CO)N
	| InChI = 1/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
	| InChIKey = XAUDJQYHKZQPEU-KVQBGUIXBH
	| StdInChI_Ref = {{stdinchicite|correct|chemspider}}		| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
	| StdInChI = 1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1		| StdInChI = 1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
Line 49:		Line 64:
	| StdInChIKey = XAUDJQYHKZQPEU-KVQBGUIXSA-N		| StdInChIKey = XAUDJQYHKZQPEU-KVQBGUIXSA-N
	}}		}}
	'''Decitabine''' (trade name '''Dacogen'''), or '''5-aza-2'-deoxycytidine''', is a ] analog.
			'''Decitabine''' (i.e., '''5-aza-2′-deoxycytidine'''), sold under the brand name '''Dacogen''' among others, acts as a nucleic acid synthesis inhibitor.<ref>{{Cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/451668|title=Decitabine|website=National Center for Biotechnology Information|access-date=September 24, 2016}}</ref> It is a ] for the treatment of ], a class of conditions where certain blood cells are dysfunctional, and for ] (AML).<ref name=EC-AML>{{cite news|title=EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia|url=http://www.rttnews.com/1973982/ec-approves-marketing-authorization-of-dacogen-for-acute-myeloid-leukemia.aspx?type=qf|access-date=28 September 2012|date=2012-09-28}}</ref> Chemically, it is a ] ].
	==Mechanism==
⚫	It is a ].<ref name="pmid16532500">{{cite journal |author=Kantarjian H, Issa JP, Rosenfeld CS, ''et al.'' |title=Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study |journal=Cancer |volume=106 |issue=8 |pages=1794–803 |year=2006 |month=April |pmid=16532500 |doi=10.1002/cncr.21792}}</ref><ref name="pmid12879469">{{cite journal |author=Kantarjian HM, O'Brien S, Cortes J, ''et al.'' |title=Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia |journal=Cancer |volume=98 |issue=3 |pages=522–8 |year=2003 |month=August |pmid=12879469 |doi=10.1002/cncr.11543}}</ref> It hypomethylates DNA by inhibiting ].
		⚫	==Medical uses==
⚫	It functions in a similar manner to ], although decitabine can only be incorporated into DNA strands while azacitidine can be incorporated into both DNA and RNA chains.
		⚫	Decitabine is used to treat ] (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (], ], ], ], and ]) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups. In patients with chronic kidney disease, Batty and colleagues reported the first case series on the feasibility of therapy with hypomethylating agents in patients with chronic kidney disease.<ref>{{cite journal | vauthors = Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F | display-authors = 6 | title = Feasibility of therapy with hypomethylating agents in patients with renal insufficiency | journal = Clinical Lymphoma, Myeloma & Leukemia | volume = 10 | issue = 3 | pages = 205–210 | date = June 2010 | pmid = 20511166 | pmc = 3726276 | doi = 10.3816/CLML.2010.n.032 }}</ref>
			It also has EU approval for ] (AML).<ref name=EC-AML/>
⚫	==Clinical uses==
⚫	Decitabine is indicated for the treatment of ] (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (], ], ], ], and ]) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups.
	==Chemical Synth==		==Pharmacology==
			{{refimprove section|date=December 2018}}
		⚫	Decitabine is a ].<ref name="pmid16532500">{{cite journal | vauthors = Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, Shen L, Nimer SD, Leavitt R, Raza A, Saba H | display-authors = 6 | title = Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | journal = Cancer | volume = 106 | issue = 8 | pages = 1794–1803 | date = April 2006 | pmid = 16532500 | doi = 10.1002/cncr.21792 | s2cid = 9556660 | doi-access = free }}</ref><ref name="pmid12879469">{{cite journal | vauthors = Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M | display-authors = 6 | title = Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia | journal = Cancer | volume = 98 | issue = 3 | pages = 522–528 | date = August 2003 | pmid = 12879469 | doi = 10.1002/cncr.11543 | s2cid = 1149318 | doi-access = free }}</ref> It hypomethylates DNA by inhibiting ].
		⚫	It functions in a similar manner to ], although decitabine can only be incorporated into DNA strands while azacitidine can be incorporated into both DNA and RNA chains.
	]
			It incorporates into DNA strands upon replication, and then when DNA methyltransferases (DNMTs) such as DNMT1, are engaged to bind the DNA and to replicate the methylation to the daughter strand, DNMTs are bound to decitabine irreversibly and cannot disengage. Therefore, the action of decitabine is division-dependent, meaning the cells have to divide in order for the pharmaceutical to act.
	Piml, J.; Sorm, F.; Coll. Czech. Chem. Commun. 1964, 29, 2576.
			Therefore, cancer cells which divide much more rapidly than most other cells in the body will be more severely affected by decitabine just because they replicate more. It seems that DNA hypermethylation is critical for development of cancer cells, and specifically for haematological malignancies. Methylation of CpG islands upstream of tumor suppressor genes in order to silence them seems to be critical for these type of cancers. Thus at optimal doses, decitabine blocks this type of methylation and has an anti-] effect.
	== Further reading ==		== Research ==
			===Atherosclerosis===
⚫	*{{cite journal |author=Moon C, Kim SH |title=Use of epigenetic modification to induce FOXP3 expression in naïve T cells |journal=Transplant Proc. |volume=41 |issue=5 |pages=1848–54 |year=2009 |month=June |pmid=19545742 |doi=10.1016/j.transproceed.2009.02.101 }}
			A number of investigators have shown a relationship between ] and disturbed blood flow. This upregulates DNA ] expression, which leads to genome-wide DNA methylation alterations and global gene expression changes. These studies have revealed several mechanosensitive genes, such as HoxA5, Klf3, and Klf4, whose promoters were hypermethylated by disturbed blood flow, but rescued by DNA methyltransferases inhibitors such as 5-aza-2'-deoxycytidine. It has been found that use of this DNA methyltranferase inhibitor prevents atherosclerosis lesion formation and reduces the production of inflammatory ]s by ].<ref>{{cite journal | vauthors = Dunn J, Thabet S, Jo H | title = Flow-Dependent Epigenetic DNA Methylation in Endothelial Gene Expression and Atherosclerosis | journal = Arteriosclerosis, Thrombosis, and Vascular Biology | volume = 35 | issue = 7 | pages = 1562–1569 | date = July 2015 | pmid = 25953647 | pmc = 4754957 | doi = 10.1161/atvbaha.115.305042 }}</ref>
	==References==		== References ==
	{{reflist}}		{{reflist}}
			== Further reading ==
	==External links==
		⚫	* {{cite journal | vauthors = Moon C, Kim SH, Park KS, Choi BK, Lee HS, Park JB, Choi GS, Kwan JH, Joh JW, Kim SJ | display-authors = 6 | title = Use of epigenetic modification to induce FOXP3 expression in naïve T cells | journal = Transplantation Proceedings | volume = 41 | issue = 5 | pages = 1848–1854 | date = June 2009 | pmid = 19545742 | doi = 10.1016/j.transproceed.2009.02.101 }}
	*
	{{Intracellular chemotherapeutic agents}}		{{Intracellular chemotherapeutic agents}}
			{{Portal bar | Medicine}}
	]		]
	]		]
	]		]
			]
			]
			]
	{{antineoplastic-drug-stub}}
			]
			]
	]